Antiviral drug

Exscientia Receives Open Philanthropy Grant to Explore New Therapeutic Approach for Pandemic Influenza

Retrieved on: 
Tuesday, December 5, 2023
Health, Infectious Diseases, Other Health, General Health, Clinical Trials, Pharmaceutical, Biotechnology, Pandemic, Novo Nordisk Foundation, Global health, Research, Open Philanthropy (organization), PAD, Bill, Epithelium, COVID-19, Therapy, Science, Virus, Infection, Cell, Antiviral drug, Pharmaceutical industry, Vaccine

Exscientia plc (Nasdaq: EXAI) announced today that the Company received a $2.3 million grant from Open Philanthropy, a philanthropic funder with several programs in global health and wellbeing.

Key Points: 
  • Exscientia plc (Nasdaq: EXAI) announced today that the Company received a $2.3 million grant from Open Philanthropy, a philanthropic funder with several programs in global health and wellbeing.
  • Under this grant, Exscientia aims to harness the activation of the host interferon response as a therapeutic approach for pandemic influenza.
  • The grant comes in the context of the wider Pandemic Antiviral Discovery (PAD) initiative.
  • This focus aligns with the company’s ongoing commitment to pandemic preparedness, initiated with support from the Bill & Melinda Gates Foundation in 2021.

Study published in Antiviral Research supports promise of Scinai Immunotherapeutics' coronavirus NanoAb as aerosolized prophylactic and therapeutic drug

Retrieved on: 
Monday, December 11, 2023
China Biologic Products, VHH, Aerosol, CDMO, Psoriasis, Antiviral Research, University Medical Center, Inflammation, Inhalation, COVID-19, Omicron, Infection, Antiviral drug, SARS-CoV-2, Max Planck Society, I&I, Single-domain antibody, Coronavirus, Arthritis, Weight loss, UMG, Vaccine, Pharmaceutical industry

JERUSALEM, Dec. 11, 2023 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI), a biopharmaceutical company focused on development of inflammation and immunology (I&I) biological products, is pleased to announce the publication following peer-review of an article titled "Nanobodies to multiple spike variants and inhalation of nanobody-containing aerosols neutralize SARS-CoV-2 in cell culture and hamsters" in the prestigious scientific journal Antiviral Research.

Key Points: 
  • The Antiviral Research paper covers several aspects of the NanoAbs, including their structure, mechanism of action, neutralization of a wide range of SARS-CoV-2 variants including Omicron, production in yeast, and formulation into aerosols.
  • "Our next pipeline project is an anti-IL-17 NanoAb for the treatment of autoimmune diseases such as plaque psoriasis and psoriasis arthritis.
  • Amir Reichman, CEO of Scinai, added "The publication of this prestigious journal article comes at an auspicious time for our company.
  • It is currently undergoing copyediting and typesetting and will soon be updated with the final version at this same link.

Bird Flu Treatment Market Research Report 2023: Antivirals, Combination Treatment, Prophylactic Antibiotics - Global Forecast to 2030 - ResearchAndMarkets.com

Retrieved on: 
Thursday, April 13, 2023
Pharmaceutical, Health, Veterinary, Research report, Customer support, Use, Culture, Value, Antibiotic, Antiviral drug, Combination, Business Growth Fund, USD, Mergers and acquisitions, Collaborative partnership, Strategic management, Pathfinder, Hospital, Investment, News, Market share analysis, Marketing, Retail

The "Bird Flu Treatment Market Research Report by Type (Antivirals, Combination Treatment, Prophylactic Antibiotics), End-User (Clinics, Hospital, Institutional Health Centers) - Global Forecast 2023-2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Bird Flu Treatment Market Research Report by Type (Antivirals, Combination Treatment, Prophylactic Antibiotics), End-User (Clinics, Hospital, Institutional Health Centers) - Global Forecast 2023-2030" report has been added to ResearchAndMarkets.com's offering.
  • The report on the Global Bird Flu Treatment Market identifies key attributes about the customer to define the potential market and identify different needs across the industry.
  • This research report categorizes the Global Bird Flu Treatment Market in order to forecast the revenues and analyze the trends in each of the following sub-markets:
    The FPNV Positioning Matrix evaluates and categorizes vendors in the Global Bird Flu Treatment Market.
  • The Global Bird Flu Treatment Market FPNV Positioning Matrix representation/visualization further aids businesses in better decision-making and understanding the competitive landscape.

Generate Biomedicines Grows Leadership Team with Head of Vaccines and Infectious Disease Research and Senior Vice President of Technical Operations

Retrieved on: 
Tuesday, November 22, 2022
Research, Infectious Diseases, Clinical Trials, Health Technology, Biotechnology, Other Health, Health, Pharmaceutical, Science, Infection, HIV, Boston Scientific, GlaxoSmithKline, Plant, Merck, Senior, Center for Global Infectious Disease Research, Flagship Pioneering, Control engineering, Ithaca College, Biochemistry, Engineering, Generate, Cytomegalovirus, Tufts University, Patient, State university system, Science, GSK, Hypertensive emergency, CMC, Research, Investigational New Drug, Society, Dream Chemistry Award, Antiviral drug, Hepatitis C, Biomedicine, IND, Biology, Protein, Drug development, Therapy, Growth, Boston Business School, Labs, Education, Drug discovery, Acceleron Pharma, History, American Society for Microbiology, State University of New York Upstate Medical University, Pharmaceutical industry, Vaccine, Microbiology

Generate Biomedicines today announced that Daria Hazuda, Ph.D., has been named Head of Vaccines and Infectious Disease Research and Lisa Wyman has been named Senior Vice President of Technical Operations.

Key Points: 
  • Generate Biomedicines today announced that Daria Hazuda, Ph.D., has been named Head of Vaccines and Infectious Disease Research and Lisa Wyman has been named Senior Vice President of Technical Operations.
  • As the company advances into its next stage of growth, Dr. Hazuda is identifying and prioritizing the best applications of the Generate platform in vaccines and infectious disease research.
  • Prior to Ms. Wyman joining Generate, she served as the Senior Vice President of Technical Operations at Acceleron Pharma.
  • Generate Biomedicines was founded by Flagship Pioneering after two years of foundational research in its Labs unit and launched in 2020.

Next-Generation Sequencing Applications for Antiviral Drug Development & FDA Guidance for Data Submission, Upcoming Webinar Hosted by Xtalks

Retrieved on: 
Wednesday, October 26, 2022
Disease, Infection, Patient, RSV, Sanger, RNA, Division, Doctor of Philosophy, NGS, Industry, US, Food, Antiviral drug, FDA, Data analysis, Pharmaceutical industry, Risk management

TORONTO, Oct. 26, 2022 /PRNewswire-PRWeb/ -- Accurate detection and monitoring of minority variants that confer drug and antiviral resistance is critical to therapeutic and vaccine trials. Specifically, it aids in controlling the emergence of novel variants that can potentially lead to outbreaks of disease and breakthrough infections. Gene variants can compromise virologic response and impact clinical outcomes.

Key Points: 
  • The featured speaker will review NGS procedures and data submissions in support of resistance assessments for antiviral drug development.
  • The speaker will also discuss the US FDA's guidance for NGS data submissions to the Division of Antiviral Products.
  • To learn more about the applications of this NGS assay and get FDA guidance on data submission, register for this webinar on antiviral drug development.
  • For more information, or to register for this event, visit Next-Generation Sequencing Applications for Antiviral Drug Development & FDA Guidance for Data Submission .

Enanta Pharmaceuticals Presents Preclinical Data for its Respiratory Syncytial Virus (RSV) and Human Metapneumovirus (hMPV) Programs at the 12th International RSV Symposium

Retrieved on: 
Thursday, September 29, 2022
Science, Biotechnology, Research, Pharmaceutical, Health, COVID-19, Infectious Diseases, Clinical Trials, Drug resistance, HCV, Development, Doctor of Philosophy, 3D, A2, COVID-19, Cytokine, IC50, Respiratory syncytial virus, Virology, Institute of Liver and Biliary Sciences, Severe acute respiratory syndrome coronavirus 2, Poster, HBV, Industry, Treatment, Degenerative disease, U.S. Securities and Exchange Commission, RSV, Infection, Program, Risk, Viral load, Human, Hepatitis B virus, Pathology, Medication, Leadership, Epithelium, Science, NASDAQ, Â, Glecaprevir/pibrentasvir, Antiviral drug, Research, Security (finance), AbbVie, Drug discovery, Patent, International, EC50, Pharmaceutical industry, Vaccine, Perfume

An oral presentation and poster highlight the preclinical characteristics and the in vivo efficacy of EDP-323, a novel non-nucleoside RSV L-inhibitor.

Key Points: 
  • An oral presentation and poster highlight the preclinical characteristics and the in vivo efficacy of EDP-323, a novel non-nucleoside RSV L-inhibitor.
  • These data continue to demonstrate our leadership in the respiratory virology field, and support and facilitate continued development of our RSV and hMPV programs.
  • EDP-323 also inhibited virus-induced cytopathic effect of RSV-A and RSV-B strains and clinical isolates with EC50s of 0.044-0.36 nM in HEp-2 cells.
  • Enantas research and development programs include clinical candidates currently in development for the following disease targets: respiratory syncytial virus (RSV), SARS-CoV-2 (COVID-19) and hepatitis B virus (HBV).

Global Liver Disease Treatment Market Report 2022-2027: Rise in Incidence of Liver Diseases & Increase in Government and Non-government Awareness Programs Driving Growth - ResearchAndMarkets.com

Retrieved on: 
Wednesday, September 7, 2022
Health, Pharmaceutical, Treatment, Market development, Antiviral drug, Observation, Porter's five forces analysis, NAFLD, Autoimmune disease, USD, Others, Genetic disorder, Ansoff Matrix, Investment, Emotion, SWOT, CAGR, Vaccine, Risk, COVID-19, Non-alcoholic fatty liver disease, Growth, Industry, Pet, Retail, Pharmaceutical industry, Risk management, Cancer, Hepatitis, Disease, Geography, Antibody

Market dynamics are forces that impact the prices and behaviors of the Global Liver Disease Treatment Market stakeholders.

Key Points: 
  • Market dynamics are forces that impact the prices and behaviors of the Global Liver Disease Treatment Market stakeholders.
  • The Global Liver Disease Treatment Market is segmented based on Disease, Treatment, and Geography.
  • By Disease, the market is classified into Hepatitis, Autoimmune Diseases, Non-alcoholic Fatty Liver Disease (NAFLD), Cancer, Genetic Disorders, and Others.
  • The report presents a detailed Ansoff matrix analysis for the Global Liver Disease Treatment Market.

Global Bird Flu Treatment Market Research Report to 2027 - Players Include Aurobindo Pharma, BioCryst Pharmaceuticals, Bristol-Myers Squibb and Chewy - ResearchAndMarkets.com

Retrieved on: 
Wednesday, July 6, 2022
Health, Pharmaceutical, Acquisition, Decision-making, Antibiotic, USD, Strategic management, Market share analysis, Value, Antiviral drug, Business Growth Fund, R, COVID-19, Customer support, Growth, Investment, Certification, CAGR, Bird Flu, Use, Compound annual growth rate, Pet, Retail, Medical device, Poultry

What are the inhibiting factors and impact of COVID-19 shaping the Global Bird Flu Treatment Market during the forecast period?

Key Points: 
  • What are the inhibiting factors and impact of COVID-19 shaping the Global Bird Flu Treatment Market during the forecast period?
  • Which are the products/segments/applications/areas to invest in over the forecast period in the Global Bird Flu Treatment Market?
  • What is the market share of the leading vendors in the Global Bird Flu Treatment Market?
  • What modes and strategic moves are considered suitable for entering the Global Bird Flu Treatment Market?

ELETTRONICA GROUP AND LENDLEASE TOGETHER IN THE BIO-DEFENSE OF PEOPLE AGAINST THE PANDEMIC

Retrieved on: 
Monday, June 20, 2022
Musica Elettronica Viva, Field line, Viral load, Antiviral drug, Omicron, Technology, CE, School, CEO, Built environment, Delta, Virus, Celio, Ecosystem, MIND, Health, Partnership, SAR, Group, Biodefense, Certification, Literature, Nature, Vaccine, Renewable energy, Lendlease

MILAN, June 20, 2022 /PRNewswire/ -- The path towards building a new normality after the health emergency begins today at MIND, Milan Innovation District. Elettronica Group, a world-class leader for 70 years in the electronic defense sector, and Lendlease, international real estate and urban regeneration group, asMIND developer, presented today at MIND, Milano Innovation District, E4Shield a unique technology in the world, capable of inactivating Covid 19 viruses and its variants Wuhan, Delta and Omicron and programmable in the future for new pathogens.

Key Points: 
  • E4Shieldwas conceived by the Elettronica company which, thanks to its seventy years of experience in the management of the electromagnetic spectrum, has also transferred its skills to the Biodefense sector.
  • This is one of the first innovation project born within the ecosystem MIND in Milan (Italy).
  • Collaborations with the Scientific Department of the Celio Military Polyclinic, the Sacco hospital, the Virostatics laboratories and above all with our partner Lendlease were fundamental for its development.
  • We hope that this innovative system will be the first step towards a return to a new normality".

ELETTRONICA GROUP AND LENDLEASE TOGETHER IN THE BIO-DEFENSE OF PEOPLE AGAINST THE PANDEMIC

Retrieved on: 
Monday, June 20, 2022
Musica Elettronica Viva, Field line, Viral load, Antiviral drug, Omicron, Technology, CE, School, CEO, Built environment, Delta, Virus, Celio, Ecosystem, MIND, Health, Partnership, SAR, Group, Biodefense, Certification, Literature, Nature, Vaccine, Renewable energy, Lendlease

MILAN, June 20, 2022 /PRNewswire/ -- The path towards building a new normality after the health emergency begins today at MIND, Milan Innovation District. Elettronica Group, a world-class leader for 70 years in the electronic defense sector, and Lendlease, international real estate and urban regeneration group, asMIND developer, presented today at MIND, Milano Innovation District, E4Shield a unique technology in the world, capable of inactivating Covid 19 viruses and its variants Wuhan, Delta and Omicron and programmable in the future for new pathogens.

Key Points: 
  • E4Shieldwas conceived by the Elettronica company which, thanks to its seventy years of experience in the management of the electromagnetic spectrum, has also transferred its skills to the Biodefense sector.
  • This is one of the first innovation project born within the ecosystem MIND in Milan (Italy).
  • Collaborations with the Scientific Department of the Celio Military Polyclinic, the Sacco hospital, the Virostatics laboratories and above all with our partner Lendlease were fundamental for its development.
  • We hope that this innovative system will be the first step towards a return to a new normality".